Cell proliferation in gastrointestinal mucosa

Wai Man Wong, Nicholas A Wright

Abstract
Gastrointestinal cell proliferation plays an important role in the maintenance of the integrity of the gastrointestinal system. The study of gastrointestinal proliferation kinetics allows a better understanding of the complexity of the system, and also has important implications for the study of gastrointestinal carcinogenesis. Gastrointestinal stem cells are shown to be pluripotential and to give rise to all cell lineages in the epithelium. Carcinogenesis in the colon occurs through sequential mutations, possibly occurring in a single cell—the stem cell.

Keywords: gastrointestinal mucosa; cell proliferation; stem cells

Mucosal cell proliferation is essential for the maintenance of the integrity of the gastrointestinal system. The proliferation rates of the gastrointestinal system are high, second only to the haemopoietic system, making it possible and practical to obtain accurate measurements; however, unlike the haemopoietic system, the tissue architecture allows a detailed analysis of its kinetic organisation. The study of gastrointestinal proliferation kinetics allows us to have a better understanding of the complexity of the system, and also has important implications for the study of gastrointestinal carcinogenesis, since enhanced mucosal proliferation had long been recognised as a promoter of carcinogenesis. Cell division in the gastrointestinal tract is confined to an anatomically discrete zone—the proliferative compartment. This readily identifiable anatomical position, together with its high proliferation rates, makes it an ideal system for the study of epithelial growth control and stem cell biology: stem cells in the gastrointestinal mucosa are pluripotential, having the ability to give rise to cells of more than one lineage. It is probable that stem cells are ultimately involved in carcinogenic mechanisms because once they acquire the sequential mutations required for the development of the neoplastic phenotype, it is likely to be permanent in all the daughter cells.

In this paper, we will address several issues in gastrointestinal proliferation: (1) the cell cycle; (2) stem cell concepts; (3) methods employed to measure proliferation in the gastrointestinal tract; (4) the cell production rate in the gastrointestinal mucosa; (5) the control of cell proliferation; (6) hypoproliferative and hyperproliferative states in the gastrointestinal tract; and (7) cell proliferation in gastrointestinal carcinogenesis.

The cell cycle
The process of cell division is divided into four different phase. The stage that can be easily recognised is mitosis or the M phase of the cell cycle. Cells then will enter a stage called G1, which is most variable in duration, and various biochemical events occur at this stage which regulate the duration and the termination of this phase. The next phase of the cell cycle is the S phase, in which DNA synthesis occurs, and immediately before mitosis, cells enter a short, second gap phase, known as G2, where the cell prepares for mitosis and assembles the spindle proteins. The duration of the cell cycle is mainly determined by the length of the G1 phase, the other phases being relatively constant. The great variability in the length of the G1 in different tissues suggests that it is the key element in the control of the cell cycle. It has been suggested that in late G1, genetically controlled event triggers the initiation of DNA synthesis, sometimes referred to as a transition probability event; the probability of passing through this transition is high in the gut, and thus the cells cycle rapidly.1 In the gastrointestinal system, cells eventually leave the cell cycle and differentiate, but in some tissues they may enter a resting phase, known as G0, although there is little evidence of a G0 phase in the gut. Differentiated cells are generally believed to lose their proliferative capacity, but in extreme conditions, they can be persuaded to enter the cell cycle again by expression of, for example, SV40T antigen.2

The stem cell concept
Stem cells are the cells that lay down the various cell lineages which form our tissues and organs during embryogenesis. They are responsible for the continued production of cells in tissues where constant renewal is a feature, such as the bone marrow and the gastrointestinal tract, and epithelial stem cells are especially important in the sense that most human tumours are derived from epithelial tissues, and that stem cells are considered by many to be intimately involved in carcinogenic mechanisms. Stem cells are pluripotential, or
have the ability to give rise to cells of more than one lineage, and consequently these cells should be the target of gene therapy, because then the effect of the treatment is likely to be permanent rather than transitory, as when expression is confined to the daughter cells (and Del Buono et al, unpublished data).

An important first concept is that stem cells in the gut are located in specific sites, at the origin of the cell flux; thus the base of the intestinal crypt is thought to house the stem cells. Second, stem cells form a minority population within the proliferating cell compartment of the crypt or gastric gland. The clonogenic population, or the number of cells capable of regenerating a crypt after severe irradiation damage, is small compared with the number of proliferating cells in the crypt, and experiments with mutagens, which induce phenotypic changes in colonic and small intestinal crypts, can be best explained by mutations induced in a single stem cell, or in a very small number. Third, the concept of a few basally sited crypt stem cells which supply progeny to the proliferative compartment of dividing transit cells has emerged; these cells have long cycle times compared with the other proliferating cells, divide asymmetrically, and the daughter cells migrate up the crypt, undergoing a series of divisions before leaving the cell cycle to begin differentiation towards the top of the crypt. The migration kinetics in the gastric glands is assumed to be similar, except that this occurs in two directions, upwards towards the foveola and downwards to the base of the gland.

Several experimental models support the concept of pluripotent stem cells in the gut. Kirkland showed that, in the HRA19 cell line (which derived from a moderately differentiated human colorectal carcinoma), single cells were able to differentiate into all cell lineages in the colon. Furthermore, when these cloned epithelial cells were grafted into the subcutaneous tissue of the nude mouse, within four months a tumour forms which reproduces the intestinal tissue of the nude mouse, within four months. The accurate assessment of cell turnover in the gastrointestinal tract is therefore possible that segregation of the lineages could occur by crypt fission.

The study of the spread of mutated stem cell crypts in mice after a single dose of a mutagen also gives rise to a similar conclusion—that is, a single stem cell can give rise to all crypt lineages, in both colon and small intestine.

In the stomach, the first study to address this problem was that of Thompson et al, using XY/XO mouse chimaeras. The male component of the chimaera was identified using in situ hybridisation with a digoxigenin labelled probe, pY353, which identified the high repetitive sequences of the mouse Y chromosome. Gastric glands in the mouse, as with crypts in the intestine, were found to be clonally derived. The findings were confirmed by Tatematsu et al, using C3H/HeN <-→ Balb/c chimaeric mice and differentiating the gastric glands using a C3H stain specific antigen.

Novelli et al described a very rare individual who showed the genotype XO/XY, who by coincidence also had familial adenomatous polyposis (FAP), for which he had undergone a prophylactic total colectomy at 32 years of age. Pathology material was available for analysis. A combination of karyotyping and fluorescent in situ hybridisation (FISH) on the patient’s peripheral blood lymphocytes confirmed that he was a mosaic, and also showed the Y chromosome to be dicentric. The karyotype was 45,X/46,X dic(Y)(Ypter->cen->Yq11.23:Yp11.3) and approximately 20% of peripheral blood lymphocytes were XO. A frameshift mutation at codon 1309 was also demonstrated by protein truncation assay of his adenomatous polyposis coli (APC) gene.

Using Y chromosome specific probes to perform in situ hybridisation on histological sections of small and large intestine of this individual, intestinal crypts were found to be composed of either XY or XO cells. From the thousands of intestinal crypts examined, only four mixed crypts were seen in otherwise pure XY patches. The patches of XO crypts were irregular in shape and patch size varied widely (mean patch width 1.85 crypts, range 1 to 14 crypts). Crypts examined at the patch border showed no mixed XO/XY cellularity and all epithelial cell lineages could be directly visualised as XO or XY, including columnar cells, goblet cells, and endocrine cells. Thus normal human intestinal crypts are clonal populations, derived from a single multipotent stem cell.

We can therefore conclude that in both animals and man there is evidence to show that the gastrointestinal stem cell has a distinct repertoire which includes all the main cell lineages observed in the gut; and is also responsible for the production of new intestinal crypts.

Methods of measuring cell proliferation in the gastrointestinal tract

The accurate assessment of cell turnover in humans is important for the understanding of a wide variety of physiological and pathological processes. Radioactive thymidine incorporation labels newly synthesised DNA, relying on
the assumption that every DNA synthesising cell exposed to the thymidine will incorporate it in a dose dependent manner. This is not always the case: first, the amount of unlabelled thymidine (cold thymidine) in the sample may affect the proliferation rate if present in large amounts; there is also some evidence that some cells may have the ability to retain the thymidine in a non-exchangeable form and incorporate the label at a later date. Second, there is a theoretical risk of radiation induced nuclear damage if high specific activity thymidine is used or the study is over a prolonged period. Third, reutilisation of used thymidine from dying or differentiated cells may also give misleading results. Finally, there is the possibility that thymidine may be incorporated into mitochondrial DNA or that DNA repair may be detected rather than scheduled DNA synthesis. Furthermore, the technique, which involves autoradiography, is very labour intensive.

An alternative method is to count mitotic figures or arrested metaphases in microdissected crypts. This can give similar results, but is far quicker and in many ways also more robust. The advantage of such techniques is that results are expressed on a per crypt basis, so that one does not need to count interphase cells. Furthermore, the geometric disadvantages associated with scoring crypt sections are avoided. A great advantage of the technique is that it can account for all the factors involved in cell renewal—that is, phase duration, growth fraction, and compartment size (see below). Although there are far fewer mitotic figures than DNA synthesising cells, microdissection of crypts enables all the figures in the entire crypt to be scored, and all the crypts in a sample can be quantified. In animal experiments, the gold standard is the quantification of the rate of entry of cells into mitosis using a metaphase arrest agent such as vincristine, which defines the crypt cell production rate (CCPR). If the number of animals is limited, an augmented mitotic index can be obtained by sampling two hours after vincristine administration. This method is theoretically less robust, but it is more precise and allows complex multivariate analysis.

In human studies, the use of a metaphase agent in vivo is unethical nowadays, but scoring mitotic figures in microdissected material is still a viable alternative. This is often more preferable to the several in vitro methods available for the assessment of biopsies, which are labour intensive, require the immediate incubation of the tissue, and may not even be reliable.

The use of immunohistochemical techniques enables the visualisation of specific cell cycle related antigens in tissues, with the important advantage of preserving the spatial orientation of cells. PC10 is a monoclonal antibody which recognises the proliferating cell nuclear antigen (PCNA), a protein associated with DNA polymerase and found in cycling cells. However, the results generated are highly dependent on the previous treatment of the tissue. It has been shown that PCNA immunoreactivity in non-neoplastic tissue is greatly reduced after 48 hour of fixation in formalin, and is virtually abolished after fixation for 72 hours. Staining is also greatly reduced or abolished if sections are heated to assist adherence to glass slides. Furthermore, the antigen can also be expressed in tissue adjacent to a tumour or in tissues after growth factor treatment. The Ki67 antigen is a protein of unknown function, which has been shown to be a reliable marker of cells within the cell cycle.

Its application was seriously affected by its requirement for frozen tissue, but recent developments have shown that a new monoclonal antibody against the same antigen, MIB-1, can be applied to conventional, paraformaldehyde tissue. MIB-1 has been extensively studied in human tissues; MIB-5, a more recently produced antibody, also shows positive staining in animal tissues. Ki67 is a good marker of cells in all phases of the cell cycle, and thus is a good measurement of the proportion of cells in cycle, the growth fraction.

There are still two problems associated with all the antibody techniques. The first is the difficulty in standardising immunohistochemical techniques and in setting thresholds for scoring a cell as labelled or unlabelled. The second is related to the problem of scoring the sections, as the results may be confounded by concomitant changes in crypt size. These problems can be avoided if the whole crypt is quantified by a microdissection based technique. This method was validated by the study of human intestinal biopsy samples, as well as in animal studies. Although the method counts cells in mitosis only, this is compensated for by the ability to see and score every mitosis in the crypts, so the numbers counted are quite high. It was estimated that there were up to 15 times more mitoses in whole crypts as were seen in a crypt section (fig 1). Biopsies need little special treatment, apart from the use of Carnoy’s solution for fixation. The tissue can then be stored in 70% alcohol for years. Crypt size and area can be determined by the use of a drawing tube, as can the position of mitoses in the crypt. Quantification of the drawings can be performed by using an image scanner and image analysis program. Combining all the above factors, scoring mitoses in microdissected crypts appears to be the method of choice for the study of gastrointestinal proliferation. Positional analysis can also be obtained accurately with the help of confocal microscopy in microdissected crypts.

![Figure 1](http://jcp.bmj.com/) A diagrammatic representation of a crypt in histological section illustrating the point that many more mitoses are seen in whole, microdissected crypts that in a single plane of section (from Goodlad et al., with permission).
Influx of cells onto the villus in the small intestine.

Figure 3 The kinetic factors which determine the crypt cell production rate and the net influx of cells onto the villus in the small intestine.

**PROLIFERATIVE INDEX DISTRIBUTION CURVES**

A useful modification of the proliferative index measurement in the gastrointestinal tract is the construction of a proliferative index distribution curve (fig 2). There are numerous kinetic parameters which derive from it, and even if tritiated thymidine cannot be used, as in human studies, the analysis of mitotic index distribution curves has allowed a comprehensive investigation of crypt cell kinetics in, for example, coeliac disease.13–14

The index distribution curve is drawn by selecting large number of axially sectioned crypts. Then, starting at cell position 1 in the column of cells, the cells in this crypt column are individually identified and a record kept of which cell positions contain mitotic or labelled cells, counting up to the crypt:villus junction, and the length of the crypt column is also recorded. If this is done for sufficiently large number of crypts (about 100 crypts per curve is a minimum), the labelling/mitotic index distribution curve can be drawn (fig 2).

There are several advantages to this analysis: (1) the proliferative activity within the crypt can be easily assessed; (2) an estimate can be made of the crypt growth fraction; and (3) the mitotic index distribution curve is the first step in the construction of the cumulative birth rate curve,35 36 which in turn leads to the derivation of migration rates and transit times at each cell position in the crypt, and to an estimate of the crypt cell production rate.

**THE CELL PRODUCTION RATE IN THE GASTROINTESTINAL TRACT**

Cell proliferation in the gut can be increased or decreased in a wide variety of different circumstances, in response to physiological stimuli such as altered food intake and also in pathological conditions. A classic example is the adaptation to gluten induced cell loss in coeliac disease.

There are various ways in which cell proliferation can be adjusted to increase or decrease cell production (fig 3). The crypt cell production rate, or the crypt efflux, is a function of the growth fraction, cell cycle time, and crypt size. Then the product of the crypt cell production rate and the numbers of crypts per villus—the crypt:villus ratio—will give a measurement of the villus influx. Any change of the above factors will affect the cell proliferation in the gut.

**THE CELL CYCLE TIME**

In rodent tissue, the cell cycle time in the small intestine is short, but there is still room for an increase in the cell production rate by a reduction in cell cycle time, as occurs after irradiation in the mouse. In the hyperproliferative mucosal state in the human small intestine found in coeliac disease, the cell production rate can be doubled by a halving of the cell cycle time.37–39 This observation was also found in the colonic hyperplasia that accompanies carcinogen treatment in the rat.39 In contrast, cell production rate can be decreased by lengthening of the cell cycle time, as seen in starvation.40–42

**THE GROWTH FRACTION**

The growth fraction in the gut proliferative system can be viewed from two different aspects. First, it can be viewed in terms of the whole crypt: in the slow cut off model of crypt cell proliferation, the position of the cut off zone is important in the control of proliferative compartment size. The cut off zone is where the daughter cells begin to decycle and differentiate, and thus its position controls the number of transit divisions in the system, and therefore the cell production rate of the
proliferative compartment. An upward expansion of the proliferative compartment would thus increase the number of transit divisions and hence cell production. In many hyperproliferative states this is accompanied by other changes such as a reduction in cell cycle time, with or without an increase in crypt size, as in the intestinal mucosa during continuous irradiation, or during administration of hydroxyurea, or in coeliac disease. Such a mechanism is especially important where tissue damage causes villus cell depletion. For example, a proliferative stimulus such as cytotoxic chemotherapy and whole body irradiation in mice will cause a series of oscillations of the crypt and villus populations in the mouse small intestine about the control values (fig 4). This strongly suggests that negative feedback control exists in the control of intestinal proliferation.

A very useful way of looking at the relations between crypt and villus populations was proposed by Cairnie et al in 1976: crypt cell production rate × villus cell production rate = crypt:villus ratio. How- ever, there is no evidence yet that adaptive changes such as starvation, resection, or lactation are associated with change in the crypt:villus ratio.

All the above mentioned factors or variables can change the crypt cell production rate, and they usually operate at the same time to produce net results.

Control of intestinal cell proliferation

There are three main hypotheses to account for the control of gastrointestinal epithelial cell proliferation. These are the local negative feedback from the structural to the reproductive compartments; the concept of luminal nutrition; and the effects of systemic factors.

NEGATIVE FEEDBACK CONTROL

There is considerable experimental evidence supporting a role for negative feedback in the gastrointestinal mucosa. Such a mechanism is especially important where tissue damage causes villus cell depletion. For example, a proliferative stimulus such as cytotoxic chemotherapy and whole body irradiation in mice will cause a series of oscillations of the crypt and villus populations in the mouse small intestine about the control values (fig 4). This strongly suggests that negative feedback control exists in the control of intestinal proliferation.

A very useful way of looking at the relations between crypt and villus populations was proposed by Cairnie et al in 1976: crypt cell production rate × villus cell production rate = crypt:villus ratio. However, there is no evidence yet that adaptive changes such as starvation, resection, or lactation are associated with change in the crypt:villus ratio.

All the above mentioned factors or variables can change the crypt cell production rate, and they usually operate at the same time to produce net results.

Control of intestinal cell proliferation

There are three main hypotheses to account for the control of gastrointestinal epithelial cell proliferation. These are the local negative feedback from the structural to the reproductive compartments; the concept of luminal nutrition; and the effects of systemic factors.

NEGATIVE FEEDBACK CONTROL

There is considerable experimental evidence supporting a role for negative feedback in the gastrointestinal mucosa. Such a mechanism is especially important where tissue damage causes villus cell depletion. For example, a proliferative stimulus such as cytotoxic chemotherapy and whole body irradiation in mice will cause a series of oscillations of the crypt and villus populations in the mouse small intestine about the control values (fig 4). This strongly suggests that negative feedback control exists in the control of intestinal proliferation.
delay induced by the finite crypt to villus transit time. When the villus cell population begins to become depleted, this is indicated by a vertical downward trajectory, and note that this occurs without crypt repopulation; thereafter—possibly as a result of the loss of villus cells—there is an increase in the crypt cell production rate, and crypt repopulation occurs without villus repopulation (again because of the delay induced by crypt to villus transit time). The final return to the baseline is because of villus repopulation. This analysis indicates that crypt cell proliferation does not increase until villus cell population depletion has occurred. Together with the damped oscillations mentioned above, this strongly supports the operation of a negative feedback system.

**LUMINAL NUTRITION**

The presence of food in the bowel is mandatory for the maintenance of the functional cell mass. The concept of luminal nutrition ascribes the maintenance of appropriate morphology and cell replacement to the mucosal uptake of nutrients from the gut lumen. Conceptually, it is difficult to dissect this from the functional demand hypothesis, since the influence of food in the intestinal lumen will undoubtedly induce a functional demand on the intestine, in terms of the mucosal absorptive work that the mucosa must do, as well as providing luminal nutrition. In many experiments, it is impossible to distinguish between these two hypotheses.

There is considerable evidence to support the importance of luminal nutrition: (1) the usual increase in cell production rate and villus height in the ileal remnant after partial small intestinal resection is profoundly reduced by isocaloric parental nutrition; (2) there is profound mucosal atrophy in animals during parenteral nutrition; (3) jejunal bypass, in the form of a Thiry-Vella fistula, increases villus height and crypt cell production rate in the bowel in continuity, while the bypassed intestine shows hypoplasia with a decreased crypt cell production rate and (4) transposition of the ileal segments to the jejunum, where nutrients are in greater concentration, results in an increase in villus height and crypt cell production rate; jejunal-ileal transposition has the converse effect.

From the growth control point of view, we need to distinguish between luminal nutrition and mucosal workload or functional demand. Perfusion experiments using glucose, galactose, and mannose provide evidence to support the functional demand or work load hypothesis. Furthermore, fibre-free elemental diets are associated with enteral atrophy, which is reduced by the addition of dietary fibre, but not by inert bulk. The magnitude of the trophic effect depends on the fermentability of the fibre, an effect of short chain fatty acids, which are products of microbial fermentation by the microbiological flora. The response is abolished in the germ-free rat, confirming that it is products of the microbial fermentation of fibre, not fibre itself, that stimulate gastrointestinal proliferation.

Direct infusion studies of short chain fatty acids have confirmed this hypothesis. A second effect of fibre is to stimulate intestinal muscle mass, a third effect is a direct, trophic effect on cell division in the stomach.

Several other nutritional factors may also influence intestinal epithelial cell proliferation. Dietary calcium supplements decrease the colonic proliferation in rodents but human data are still inconclusive. Omega-3 fish oils may also decrease colonic proliferation, perhaps by modulating prostaglandin synthesis. The modulation of prostaglandin synthesis in the colon may be protective against the development of cancer, as suggested by the beneficial effect of aspirin in the colon. Recently, lectins—which are carbohydrate binding proteins present in plants (particularly in seeds, young shoots, and bark, and in animal and human tissues, where they perform a variety of biological functions)—have been shown to affect colonic epithelial cell proliferation. For example, peanut lectin can increase rectal proliferation, while mushroom lectin has the opposite effect. The role of vitamins has also generated considerable interest.

**SYSTEMIC FACTORS**

Gastrointestinal epithelial cell proliferation can be modulated by the local effects of hormones, peptides, and growth factors. Enteroglucagon, a 69 amino acid peptide, is part of a larger pre-proglucagon, which contains glicentin related pancreatic polypeptide (GRPP), glucagon, oxyntomodulin, and the glucagon-like peptides GLP1 and GLP2. GLP-2 has been shown to be a potent stimulant of intestinal epithelial proliferation. Gastrin is trophic to the fundic mucosa of the stomach. The introduction of proton pump inhibitors causes almost complete achlorhydria and in turn stimulates the hypersecretion of gastrin, which causes enterochromaffin-like (ECL) cell hyperplasia.
and even carcinoid formation in rodents.79–81 Besides the effect on gastric mucosa, gastrin was found to have a trophic effect to several colonic cell lines and carcinomas,82 and postprandial gastrin levels are higher in colon cancer patients.83

One of the most potent agents for stimulating gastrointestinal proliferation is epidermal growth factor (EGF). EGF is present in a variety of biological fluids, including milk, and stimulates proliferation and maturation of the pre- and postnatal intestine.84 It is a very potent stimulator of epithelial cell production in the intestine of adult rats and humans.85 86 The proliferative effects in the rat are only seen when EGF is given systemically,87 and the lack of luminal effect may be because it is either broken down in the digesta88 or more likely due to its receptors being basolateral.89 Transforming growth factor alpha (TGFα), which binds to the same receptor as EGF,90 also stimulates gastrointestinal epithelial cell proliferation but to a lesser extent.91 92

Trefoil peptides are small, secretory, stable peptides, bearing one or more trefoil structural motifs.93 They are produced rapidly at sites of injury and stimulate the repair process, particularly the early phase of epithelial restitution, possibly by inducing the migratory phenotype. In chronic ulcerative conditions such as Crohn’s disease, trefoil peptides are secreted by a specific lineage called the ulcer associated cell lineage (UACL).94–96 Interestingly, these UACL glands also secrete EGF and TGFα, all potentially contributing to the healing process.

Prostaglandins can increase gastric cell proliferation and cell migration,97 98 and they stimulate proliferation in the small bowel but not in the colon.99 100

**Figure 6** The effect of starvation and refeeding on the labelling index distribution curve in the rat: (A) at 4 hours after starvation; (B) after 96 hours starvation; (C) 8 hours after refeeding; (D) at 16 hours after refeeding. (From Al-Dewachi et al.,10 with permission.)

**Hyperproliferative states in the gastrointestinal mucosa**

The most striking growth response in the human small intestine is seen in coeliac disease. The characteristic histopathological features are a flat avillous duodeno-jejunal mucosa on stereomicroscopy, usually with a mosaic pattern, and with distinctive histological change: total villus atrophy, crypt hyperplasia, and a prominent infiltration of the lamina propria with plasma cells and lymphocytes. In this interesting condition, we have a mucosa which shows hyperplasia of one component only, the crypts, while the villi are effectively absent as discrete anatomical structures. Compared with normal controls, there is a large increase in the crypt column length and in the column count, indicating a threefold expansion of the crypt population.15 16 There is a significant increase in mitotic index, and inspection of mitotic index distribution curves suggests that the crypt growth fraction is decreased in the flat
mucosa. Because of the expanded crypt population, there is also a threefold increase in the number of proliferative cells in the enlarged crypts. This would raise the crypt cell population by threefold. The number of cells in the maturation compartment is also increased.

By using the metaphase arrest method and FLM method, the cell cycle time was shown to be halved in the flat mucosa (~24 hours) compared with some 48 hours in controls. The doubling of crypt cell production rate by this change, coupled with the threefold increase produced by the expansion in the proliferative compartment, accounts for the fivefold increase in the crypt cell production rate. Interestingly, in the less severe form of the disease, in which the mucosal biopsy showed a large number of convolutions, there is a moderate increase in proliferative cellularity and a more modest decrease in the cell cycle time.

It appears that the initial event in the production of these abnormal mucosae is an increase in the surface cell loss rate. The degree of the cell loss determines the villus morphology, with minor levels resulting in convolutions, and severe injury resulting in the flat mucosa of coeliac disease. The crypt morphology is explained in terms of the cell kinetics, with large increases in the proliferative cellularity produced by crypt enlargement; also contributing to the cell production is a large reduction in cell cycle time.

Multifocal gastritis of the stomach caused by Helicobacter pylori may lead to development of atrophic gastritis, then to intestinal metaplasia, dysplasia, and finally to the development of gastric cancer. The whole spectrum of this pathology in the stomach is also hyperproliferative (see below).

In active ulcerative colitis, there is also a hyperproliferative state, and one result of this is that there is insufficient time for the daughter cells to differentiate, resulting in goblet cell depletion. There is no doubt that in patients with long standing ulcerative colitis, with the colon still in situ, the risk of colorectal carcinoma is increased. In active disease, the labelling index is increased, the turnover time is reduced, and the proliferative compartment expanded and moved upwards, as indicated by the position of the labelled cells in the crypt.

Cell proliferation in gastrointestinal carcinogenesis

Most cells in the gastrointestinal epithelium have a limited life span, being extruded at the villus or colonic surface. The number of mutations required to provoke neoplastic change is still uncertain, but the age distribution of the incidence of gastrointestinal neoplasms suggests that this process lasts a significant time. The only cells which will remain in the crypt long enough to accumulate sequential mutations are the stem cells, as all other cells will be lost on the escalator. If a stem cell accumulates sufficient mutations to repopulate the crypts as a monocyral adenoma, a crypt fission event which segregates the progeny of this stem cell into a daughter crypt will perform mean that neoplastic stem cells will be present in the daughter crypt. Thus the stem cells are probably the targets for carcinogens to act upon.

In experimental animals, it is relatively easy to induce tumours in the stomach and colon, but quite difficult in the small intestine. This pattern is reproduced in human gut cancer. A possible reason for this singular distribution could be the difficulty of a transformed cell establishing a carcinogenic advantage in the rapidly proliferating small intestinal crypt, or the problems experienced by a crypt full of transformed stem cells re-colonising an adjacent crypt by growing downwards against the prevailing current of cell migration.

Much of our knowledge of cell proliferation during carcinogenesis in the gut comes from the use of experimental models. In the colon, the most valuable of these is the 1,2-dimethylhydrazine (DMH) model. The incidence of colonic neoplasms is almost 100% in any dosage schedule. In the rat the neoplasms tend to be more isolated, whereas in the mouse they are widespread. A similar model is azoxymethane, also given subcutaneously on a weekly basis, which shows a similar distribution of lesions. In the experimental production of gastric cancer, the tumourigenic agent has been N-methyl-N'-nitro-nitrosoguanidine (MNNG).

The acute effect of carcinogens on gastrointestinal epithelia is the inhibition of DNA synthesis. Histological examination shows prominent necrosis of the crypt cells in both large and small intestinal mucosae, extensive within six hours of treatment and recovering over the next 24 hours. The damage appears localised to the proliferative compartment of the crypt. This is followed by a prominent compensatory proliferative response, resulting in crypt hyperplasia. A similar sequence of events has been described in the glandular stomach of the rat after application of acetomethyl-methyl nitrosamine.

Chronic treatment with suitable carcinogens (for example, weekly injection of DMH) leads to a variety of hyperplastic changes in gastrointestinal epithelia. It is widely considered that the dysplastic change, which eventually leads to invasive carcinoma, results directly from the hyperplastic mucosa. The hyperplasia during this phase is mediated by an increase in the crypt size, and is proportional to the duration of DMH treatment. The normal pattern of differentiation is preserved in these hyperplastic crypts, but there is an increased labelling index with upward shifting of labelled cells to the top of the crypt. Studies of the labelling index distribution curves indicate that the growth fraction is actually reduced in these crypts, but because of the increase in crypt size, there is either no change, or a small increase, in the absolute number of proliferating cells in the crypt. Analysis of the cell cycle in the rat DMH model showed that there was no change in cell cycle time in the small intestinal crypt but a general shortening of the cell cycle time in the colon, being more pronounced in the distal than the proximal colon. Thus in the colonic DMH model, there is a sustained
hyperplasia during carcinogenesis, with a progressive reduction in the cell cycle time until, with the evolution of frankly neoplastic cells, the cell cycle time is decreased enough to confer a definite carcinogenic advantage.

So, if hyperplasia is considered important, what are the effects of hyperplasia itself upon carcinogenesis? Williamson had addressed this problem on a systematic basis, noting that the compensatory responses to manoeuvres such as small bowel resection were accompanied by hyperplastic changes in the colon; resected animals showed an increase in the prevalence of colonic tumours on DMH treatment. Interestingly, defunctioning of bowel segments showed a decrease in the incidence of colonic tumours in experimental animals treated with carcinogens. It thus appears that the initial proliferative status of the mucosa is an important variable in carcinogenesis in the colon.

In the human situation, in both the stomach and the colon there are well recognised premalignant lesions. These are characterised by increased proliferation rates, which are thought to be associated with a greater chance of developing carcinoma. In the stomach, this lesion is intestinal metaplasia, with or without the association of chronic atrophic gastritis, while in the colon, chronic ulcerative colitis and benign adenomas of colon are associated with increased cancer risk. In the colon, patients with ulcerative colitis show evidence of an increased proliferative rate as described above. Thus intestinal metaplasia and ulcerative colitis are both lesions with raised proliferative rates, and hyperplasia itself is a promoter of gastrointestinal carcinogenesis, possibly acting through the abolition of genetic housekeeping in gastrointestinal stem cells, and the hyperplasia itself may be responsible for the association with increased cancer incidence. However, apart from de novo cancers that develop in ulcerative colitis, most malignant colonic tumours develop from a non-invasive adenoma. By in vitro labelling studies and PCNA and Ki67 immunostaining, labelling indices, it is generally claimed that there is progression in the proliferative rate from normal mucosa to adenoma and then to carcinoma. In the well established model described by Fearon and Vogelstein there are progressive genetic changes during the progression of adenoma to carcinoma in situ to invasive carcinoma.

In intestinal metaplasia the gastric mucosa undergoes a change to resemble that in the small intestine, complete with goblet and Paneth cells, though rarely with villi. In these intestinalised glands, labelled cells are confined to the lower portion, and there is a marked increase in proliferative activity, as evidenced by high in vitro labelling indices and Ki67 immunostaining. Some patients have expanded proliferative compartments, with DNA synthesis in surface cells, while in severe atrophic gastritis with intestinal metaplasia there is a reversion of the labelling index distribution curve to the format seen in the normal small bowel crypt. The birth rate in areas of intestinal metaplasia is two or three times the normal level. We can conclude that intestinal metaplasia is a hyperproliferative state.

Detailed study of the histogenesis of intestinal metaplasia showed that in early lesions, some glands have metaplastic features in their upper portion only, while the lower part of the gland remains occupied with normal pyloric cells; labelled cells are seen in the isthmus of these glands, and the Paneth cells appear just below this proliferative zone; thus the process begins in the original proliferative area of the gastric gland, through a change in the differentiation pattern of the gastric proliferating cells in this area. The proliferative zone then moves to the gland base, and the gland then fully resembles a small intestinal crypt. Intestinalisation is associated with the formation of cystic structures, which three dimensional analysis has shown to be completely separated from the gastric lumen, and to contain proliferating cells. Fujita and Hatton have suggested that the sequestration of transformed cells in these areas allows the evolution of neoplasia in spite of the continuous removal of cells in the general escalator. There is no doubt that dysplastic changes occur in areas of atrophic gastritis and intestinal metaplasia. Increasing severity of dysplasia is associated with a progressively increasing cell population rate, with a resulting decrease in the turnover time and an expansion of the proliferative compartment, until in severe dysplasia all cells including surface cells appear proliferative. Invasive carcinoma may then evolve from this stage.

In the colon, patients with ulcerative colitis show evidence of an increased proliferative rate as described above. Thus intestinal metaplasia and ulcerative colitis are both lesions with raised proliferative rates, and hyperplasia itself is a promoter of gastrointestinal carcinogenesis, possibly acting through the abolition of genetic housekeeping in gastrointestinal stem cells, and the hyperplasia itself may be responsible for the association with increased cancer incidence. However, apart from de novo cancers that develop in ulcerative colitis, most malignant colonic tumours develop from a non-invasive adenoma. By in vitro labelling studies and PCNA and Ki67 immunostaining, labelling indices, it is generally claimed that there is progression in the proliferative rate from normal mucosa to adenoma and then to carcinoma. In the well established model described by Fearon and Vogelstein there are progressive genetic changes during the progression of adenoma to carcinoma in situ to invasive carcinoma. It appears that this hyperproliferative state—a progressive accumulation of a series of somatic mutations in the stem cells, which have a long residence time in the mucosa—will eventually lead to the development of the malignant phenotype, possessing some growth advantage over other stem cells within the crypt or gland. Alternatively, an initial mutation, such as one leading to loss of heterozygosity of the APC gene in a colonic epithelial cell, then spreads through the crypt merely by a stochastic process in which the crypt becomes occupied by a monoclonal population of such cells. This monoclonal conversion event has been documented in animals injected with mutagens, and following the development of mutated clones in the colonic crypts, by using gene products such as glucose-6-phosphate dehydrogenase (G6PD) or the binding of DBA. Once the mutated clone is established, it is proposed that this spread occurs by a process of crypt fission, in which the crypt divides into two, and thus the mutated clone spreads through the mucosa (fig 7) There is also documented human evidence that large areas of colonic mucosa are colonised by dysplastic crypts containing a single aneuploid stem line. Moreover, the pre-dominant mode of growth of adenomas is also by fission of the adenomatous crypts. Interestingly, in FAP colon, detailed microdissection studies show that the major abnormality observed is an increased crypt fission index and not an increase in crypt epithelial cell...
proliferation rate. There is also no difference between FAP colonic mucosa and the controls in the distribution of mitotic figures. Furthermore, a recent study by Jass and colleagues has shown that there is no difference in Ki67 labelling index between patients with hereditary non-polyposis colorectal cancer and subjects with some positive family history of colorectal cancer.143 Thus it appears that hyperproliferation is not a general phenomenon in the early step of colonic carcinogenesis, and Jass et al consider that it is unlikely that hyperproliferation plays any part in the pathogenesis of common colorectal cancers. Crypt fission may play an important role in these early events, both for the spread of the neoplastic clones and the growth of the adenomas.

There is as yet no evidence that the same process occurs in the gastric gland. But it would be reasonable to propose that a mutation in stem cells situated at the neck would spread through the gastric gland in a similar manner to that described in the colon. Furthermore, it is known that gastric glands reproduce by a process of gland fission, in which the initial budding event takes place at

Figure 7  Top panel: a section of mouse colon stained for the presence of glucose-6-phosphate dehydrogenase (G6PD) after treatment with ethyl nitrosourea; only the right hand hemi-crypt has lost staining for the enzyme, but in the middle panel the entire crypt is converted to a population of cells which are negative for G6PD; the bottom panel shows a patch of mutated crypts, negative for G6PD, which has grown by crypt fission. (From Park et al,9 with permission.)
the neck, where the stem cells are located.129
Thus, once a gastric gland is colonised by mutated cells, the gland will spread through the mucosa by gland fission, and it is likely that field cancerisation in gastrointestinal epithelia is caused by mutated clones spreading in this manner.144

Conclusion
We have come a long way in the study of proliferation of gastrointestinal mucosa, from the study of the kinetic behaviour, proliferation in different physiological and pathological conditions, to the study of the stem cell repertoire which lead us to understand and speculate on the underlying mechanism of a host of interesting conditions in the gastrointestinal tract. Perhaps in the future, the study of this elusive stem cell will give us information concerning the ultimate control of proliferation and about carcinogenic mechanisms, and will lead to successful and stable gene transfer in clinical use.

This work was supported by the Imperial Cancer Research Fund and the Croucher Foundation Fellowship to WMW, who is presently affiliated to the Department of Medicine, Queen Mary Hospital, University of Hong Kong.


137 Deschner EE, Maskens AP. Significance of the labelling index and labelling distribution as kinetic parameters in colorectal mucosa of cancer patients and DMM treated mice. *Int J Cancer* 1982;30:156–61.


